blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2393488

EP2393488 - THERAPEUTIC COMPOSITIONS COMPRISING MONOTERPENES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 12.07.2024
FormerThe patent has been granted
Status updated on  17.05.2019
FormerGrant of patent is intended
Status updated on  24.10.2018
FormerExamination is in progress
Status updated on  07.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
University Of Southern California
3740 McClintock Avenue, EEB 131
Los Angeles, CA 90089-2561 / US
[2011/50]
Inventor(s)01 / CHEN, Thomas C.
c/o University of Southern California
3740 McClintock Avenue EEB 131
Los Angeles, California 90089-2561 / US
02 / DA FONSECA, Clovis O.
Rua Alberto Bianchi 57/101
CEP 22795-390 Rio de Janeiro / BR
03 / DOS SANTOS, Thereza Quirico
Rua Fernandes Couto 261
Sao Francisco
Niteroi
CEP 24365-150 Rio de Janeiro / BR
04 / SCHWARTSMANN, Gilberto
Rua Santo Inacio 525/1021
CEP 90570-150 Porto Alegre / BR
 [2011/50]
Representative(s)Tomkins & Co
5 Dartmouth Road
Dublin 6 / IE
[2019/25]
Former [2011/50]Gates, Marie Christina Esther, et al
Tomkins & Co. 5 Dartmouth Road
Dublin 6 / IE
Application number, filing date10703598.204.02.2010
[2019/25]
WO2010US23228
Priority number, dateUS20090150714P06.02.2009         Original published format: US 150714 P
[2011/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010091198
Date:12.08.2010
Language:EN
[2010/32]
Type: A1 Application with search report 
No.:EP2393488
Date:14.12.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 12.08.2010 takes the place of the publication of the European patent application.
[2011/50]
Type: B1 Patent specification 
No.:EP2393488
Date:19.06.2019
Language:EN
[2019/25]
Search report(s)International search report - published on:EP12.08.2010
ClassificationIPC:A61K47/10, A61K31/045, A61K31/495, A61P35/00
[2018/42]
CPC:
A61K31/045 (EP,US); A61K31/415 (EP,US); A61K31/4188 (EP,US);
A61K45/06 (EP,US); A61K47/10 (EP,US); A61K9/0043 (EP,US);
A61K9/0048 (EP,US); A61K9/0073 (EP,US); A61K9/08 (EP);
A61P35/00 (EP) (-)
C-Set:
A61K31/045, A61K2300/00 (EP,US);
A61K31/415, A61K2300/00 (US,EP);
A61K31/4188, A61K2300/00 (US,EP)
Former IPC [2018/41]A61K47/10, A61K31/045, A61K31/4188, A61P35/00
Former IPC [2011/50]A61K31/045, A61K47/10, A61P35/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2011/50]
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:THERAPEUTISCHE ZUSAMMENSETZUNGEN MIT MONOTERPENEN[2011/50]
English:THERAPEUTIC COMPOSITIONS COMPRISING MONOTERPENES[2011/50]
French:COMPOSITIONS THÉRAPEUTIQUES COMPRENANT DES MONOTERPÈNES[2011/50]
Entry into regional phase05.09.2011National basic fee paid 
05.09.2011Designation fee(s) paid 
05.09.2011Examination fee paid 
Examination procedure05.09.2011Amendment by applicant (claims and/or description)
05.09.2011Examination requested  [2011/50]
21.08.2013Despatch of a communication from the examining division (Time limit: M04)
09.12.2013Reply to a communication from the examining division
11.05.2015Despatch of a communication from the examining division (Time limit: M06)
11.11.2015Reply to a communication from the examining division
28.11.2016Despatch of a communication from the examining division (Time limit: M06)
08.06.2017Reply to a communication from the examining division
16.01.2018Despatch of a communication from the examining division (Time limit: M06)
03.07.2018Reply to a communication from the examining division
07.08.2018Despatch of a communication from the examining division (Time limit: M01)
13.08.2018Reply to a communication from the examining division
25.10.2018Communication of intention to grant the patent
19.02.2019Fee for grant paid
19.02.2019Fee for publishing/printing paid
19.02.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19180373.3  / EP3620154
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.08.2013
Opposition(s)03.06.2020No opposition filed within time limit [2020/33]
Fees paidRenewal fee
22.02.2012Renewal fee patent year 03
12.02.2013Renewal fee patent year 04
08.08.2014Renewal fee patent year 05
27.02.2015Renewal fee patent year 06
30.08.2016Renewal fee patent year 07
03.08.2017Renewal fee patent year 08
25.07.2018Renewal fee patent year 09
30.04.2019Renewal fee patent year 10
Penalty fee
Additional fee for renewal fee
28.02.201405   M06   Fee paid on   08.08.2014
29.02.201607   M06   Fee paid on   30.08.2016
28.02.201708   M06   Fee paid on   03.08.2017
28.02.201809   M06   Fee paid on   25.07.2018
28.02.201910   M06   Fee paid on   30.04.2019
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.02.2010
AT19.06.2019
CY19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
MK19.06.2019
MT19.06.2019
NL19.06.2019
PL19.06.2019
RO19.06.2019
SE19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
IE04.02.2020
LU04.02.2020
BE29.02.2020
CH29.02.2020
LI29.02.2020
[2022/32]
Former [2022/27]HU04.02.2010
AT19.06.2019
CY19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
MT19.06.2019
NL19.06.2019
PL19.06.2019
RO19.06.2019
SE19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
IE04.02.2020
LU04.02.2020
BE29.02.2020
CH29.02.2020
LI29.02.2020
Former [2021/12]AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
NL19.06.2019
PL19.06.2019
RO19.06.2019
SE19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
IE04.02.2020
LU04.02.2020
BE29.02.2020
CH29.02.2020
LI29.02.2020
Former [2021/08]AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
NL19.06.2019
PL19.06.2019
RO19.06.2019
SE19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
IE04.02.2020
LU04.02.2020
CH29.02.2020
LI29.02.2020
Former [2020/52]AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
NL19.06.2019
PL19.06.2019
RO19.06.2019
SE19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
LU04.02.2020
CH29.02.2020
LI29.02.2020
Former [2020/49]AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
NL19.06.2019
PL19.06.2019
RO19.06.2019
SE19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
LU04.02.2020
Former [2020/48]AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
PL19.06.2019
RO19.06.2019
SE19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
LU04.02.2020
Former [2020/37]AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
PL19.06.2019
RO19.06.2019
SE19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/36]AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
PL19.06.2019
RO19.06.2019
SE19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/24]AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
PL19.06.2019
RO19.06.2019
SE19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
PT21.10.2019
IS24.02.2020
Former [2020/22]AT19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
RO19.06.2019
SE19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/17]AT19.06.2019
CZ19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
RO19.06.2019
SE19.06.2019
SK19.06.2019
SM19.06.2019
TR19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/13]AT19.06.2019
CZ19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
RO19.06.2019
SE19.06.2019
SK19.06.2019
SM19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/12]AT19.06.2019
CZ19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
IT19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
RO19.06.2019
SE19.06.2019
SK19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/11]AT19.06.2019
CZ19.06.2019
EE19.06.2019
ES19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
RO19.06.2019
SE19.06.2019
SK19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
PT21.10.2019
Former [2020/10]AT19.06.2019
CZ19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
RO19.06.2019
SE19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
PT21.10.2019
Former [2020/09]CZ19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
SE19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
Former [2020/07]FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
NL19.06.2019
SE19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
Former [2019/51]FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
SE19.06.2019
BG19.09.2019
NO19.09.2019
GR20.09.2019
Former [2019/50]FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
SE19.06.2019
NO19.09.2019
GR20.09.2019
Former [2019/49]FI19.06.2019
HR19.06.2019
LT19.06.2019
SE19.06.2019
NO19.09.2019
Former [2019/48]FI19.06.2019
LT19.06.2019
SE19.06.2019
NO19.09.2019
Former [2019/47]FI19.06.2019
LT19.06.2019
NO19.09.2019
Cited inInternational search[X]WO03057193  (DOR BIOPHARMA INC [US], et al) [X] 1-31 * paragraphs [0025] , [0000] , [0043] , [0048] , [0057] , [0067] , [0068] * * example 1; table 1 * * claims 1,5,6,9,13,20-22,34-35 *;
 [X]US2003180349  (FRANKLIN LANNY U [US]) [X] 1-7 * paragraphs [0121] , [0141] , [0159] * * example 9 *;
 [A]US2004087651  (PEREIRA DA FONSECA CLOVIS ORLA [BR], et al) [A] 1-31 * the whole document *;
 [A]  - DA FONSECA C O ET AL, "Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas", SURGICAL NEUROLOGY, LITTLE, BROWN AND CO., BOSTON, MA, US LNKD- DOI:10.1016/J.SURNEU.2007.07.040, vol. 70, no. 3, ISSN 0090-3019, (20080901), pages 259 - 266, (20080304), XP023613298 [A] 1-31 * abstract *

DOI:   http://dx.doi.org/10.1016/j.surneu.2007.07.040
 [A]  - CERDA S ET AL, "Enhanced antitumor of lovastatin and peryllyl alcohol combinations in the colonic adenocarccinoma cell line SW 480", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, (19940101), vol. 35, ISSN 0197-016X, page 335, XP001525195 [A] 1-31 * abstract *
by applicantUS3957856
 US4107288
 US4738851
 US4882150
 US4921475
 US5008110
 US5077033
 US5087240
 US5088977
 US5145684
 US5164189
 US5163899
 US5254346
 US5290561
 US5332213
 US5336168
 US5352456
 US5403841
 US5407713
 US5521222
 US5698219
 US5776445
 US5785991
 US5800807
 US5843468
 US5882676
 US6004578
 US6056950
 US6197934
 US6261547
 US2004087651
 US2005250854
    - HASHIZUME ET AL., NEURO-ONCOLOGY, (2008), vol. 10, pages 112 - 120
    - MCKEAGE, J. CLIN. ONCOL., (1997), vol. 201, pages 1232 - 1237
    - MCKEAGE ET AL., J. CLIN. ONCOL., (1997), vol. 201, pages 1232 - 1237
    - POMMICR, NAT. RCV. CANCER, (2006), vol. 6, no. 10, pages 789 - 802
    - LI ET AL., BIOCHEMISTRY, (2000), vol. 39, no. 24, pages 7107 - 7116
    - GATTO ET AL., CANCER RES., (1996), vol. 15, no. 12, pages 2795 - 2800
    - MAKHEY ET AL., BIOORG. MED. CHEM., (2003), vol. 11, no. 8, pages 1809 - 1820
    - XU, BIOCHEMISTRY, (1998), vol. 37, no. 10, pages 3558 - 3566
    - FOGLESONG ET AL., CANCER CHEMOTHER. PHARMACOL., (1992), vol. 30, no. 2, pages 123 - 125
    - CROW ET AL., J. MED. CHEM., (1994), vol. 37, no. 19, pages 3191 - 3194
    - CRESPI ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1986), vol. 136, no. 2, pages 521 - 8
    - POMMIER, NAT. REV. CANCER, (2006), vol. 6, no. 10, pages 789 - 802
    - DENNY; BAGULEY, CURR. TOP. MED. CHEM., (2003), vol. 3, no. 3, pages 339 - 353
    - PAPAMICHEAL, THE ONCOLOGIST, (1999), vol. 4, pages 478 - 487
    - DREVS, IDRUGS, (2003), vol. 6, no. 8, pages 787 - 794
    - BALASSIANO ET AL., INTERN. J. MOL. MED., (2002), vol. 10, pages 785 - 788
    - THOME ET AL., NEUROSCIENCE, (2004), vol. 127, pages 481 - 496
    - FERNANDES ET AL., ONCOLOGY REPORTS, (2005), vol. 13, pages 943 - 947
    - DA FONSECA ET AL., SURGICAL NEUROLOGY, (2008), vol. 70, pages 259 - 267
    - DA FONSECA ET AL., ARCH. IMMUNOL. THER. EXP., (2008), vol. 56, pages 267 - 276
    - HASHIZUME ET AL., NEURONCOLOGY, (2008), vol. 10, pages 112 - 120
    - THORNE ET AL., NEUROSCIENCE, (2004), vol. 127, pages 481 - 496
    - DA FONSECA, SURGICAL NEUROLOGY, (2008), vol. 70, pages 259 - 267
    - DA FONSECA, ARCH. IMMUNOL. THER. EXP., (2008), vol. 56, pages 267 - 276
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.